Abstract
A clinical trial of nivolumab in 10 patients with pediatric cancer with high tumor mutational burden demonstrated complete responses in 50% of patients. This result recapitulates multiple clinical trial results in high mutation-burden adult cancers and may redefine best practice in the setting of germline DNA mismatch repair-based susceptibility. See related article by Das et al., p. 4770.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical cancer research : an official journal of the American Association for Cancer Research
Paper Title
Journal
Date
